Annexon, Inc. (ANNX) recently announced promising topline findings from a real-world evidence study that supports the potential of ANX005 as a treatment for Guillain-Barré Syndrome, an acute neuromuscular disorder with rapid onset.
The study indicated that patients receiving ANX005 exhibited quicker and more significant improvements in both muscle strength and disability levels compared to those treated with IVIg or PE in the matched International GBS Outcomes Study cohort.
Furthermore, patients administered ANX005 required a shorter duration of mechanical ventilation and spent less time in intensive care units. Only a small proportion needed mechanical ventilation, underscoring the treatment's efficacy.
In light of these encouraging results, Annexon intends to file a U.S. Biologics License Application within the first half of 2025.
Following the announcement, Annexon's stock has risen by 11.15%, reaching $4.94 on the Nasdaq.
